United Laboratories Inc.

Novo Nordisk is to pay $200m upfront to in-license a ‘triple G’ agonist obesity candidate, helping it compete head-to-head with fierce rival Eli Lilly. The deal with China-based United Bio-Technology

SHANGHAI - Hong Kong-listed Lee's Pharmaceutical Holdings Ltd. and its US partner RegeneRx Biopharmaceuticals Inc. are set to benefit from China’s new rules for conducting early phases of clin

CHONGQING - Chinese military strategist Sun Tzu once said that knowing oneself, you can win half your battles; but know both sides, and you can win all battles. Perhaps heeding this advice, French dru

BEIJING – In a new sign of the local government’s willingness to control drug costs, the tender authorities in Hunan province have stirred up a controversy and in return received pushback from some pr